Amgen Rethinks Ganitumab After Longshot Pancreatic Cancer Trial Fails
Executive Summary
Hopes for IGF-1R inhibitor ganitumab had not been high due to past flops for others in the class. But research in extensive stage small-cell lung cancer and KRAS wild-type metastatic colorectal cancer goes on, at least for now.
You may also be interested in...
Deal Watch: Roche/Foundation Medicine Highlights Hyper Deal-Making During J.P. Morgan
Biogen will purchase GSK spinout Convergence to bolster its pain portfolio, while Tekmira and OnCore are merging to create a new company focused on hepatitis B. Two J&J units struck deals during the week in Alzheimer’s and gastrointestinal indications, as Lilly teamed up with Merck and Bristol for combo trials to keep its drugs relevant in the PD-1 world.
Amgen Plays Diversity Card In Approach To Cancer; Immunotherapy Could Be Its Ace
Amgen explains why it has what it takes in immunotherapy, as part of a broader oncology development plan.
Celgene’s Abraxane Scores A Win Against Tough Pancreatic Cancer
Abraxane more than doubled two-year survival and conferred a near-two-month overall survival advantage against pancreatic cancer compared with standard of care gemcitabine alone in the Phase III MPACT trial, presented Jan. 25 at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco. Celgene plans global regulatory filings by mid-2013.